Keros Therapeutics, Inc. (KROS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
KROS currently has 30.5M outstanding shares. with limited dilution risk as only 5.75M additional shares (18.9%) are authorized for issuance. The company has diluted shareholders by 12.59% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Nov 05, 2025 |
10-Q filing | 30.5M shares outstanding |
30M | 5.8M |
| Oct 15, 2025 |
8-K filing: Keros Therapeutics, Inc. has agreed to repurchase an aggregate of 10,176,595 shares of its common stock from the ADAR1 Parties and the Pontifax Parties at a price of $17.75 per share, for a total purchase price of approximately $181 million. ($181.0M proceeds) |
41M | 5.8M |
| Aug 06, 2025 |
10-Q filing | 40.6M shares outstanding |
41M | 5.8M |
| May 06, 2025 |
10-Q filing | 40.6M shares outstanding |
41M | 5.8M |
| Feb 26, 2025 |
10-K filing | 37.4M shares outstanding |
37M | 5.8M |
| Nov 06, 2024 |
10-Q filing | 37.6M shares outstanding |
38M | 5.8M |
| Aug 07, 2024 |
10-Q filing | 36.1M shares outstanding |
36M | 5.8M |
| May 08, 2024 |
10-Q filing | 35.7M shares outstanding |
36M | 5.8M |
| Feb 28, 2024 |
10-K filing | 36.0M shares outstanding |
36M | 5.8M |
| Jan 09, 2024 |
8-K filing: Keros Therapeutics, Inc. closed an underwritten public offering of 4,025,000 shares of common stock at $40.00 per share, resulting in net proceeds of approximately $151.3 million. ($151.3M proceeds) |
30M | 5.8M |
| Jan 04, 2024 |
8-K filing: Keros Therapeutics, Inc. announced the offering, issuance and sale of 3,500,000 shares of its common stock at a price of $40.00 per share, with expected net proceeds of approximately $131.2 million. ($140.0M proceeds) |
30M | 5.8M |
| Nov 06, 2023 |
10-Q filing | 29.7M shares outstanding |
30M | 5.8M |
| Aug 07, 2023 |
10-Q filing | 29.6M shares outstanding |
30M | 5.8M |
| May 04, 2023 |
10-Q filing | 28.4M shares outstanding |
28M | 5.8M |
| Mar 03, 2023 |
10-K filing | 28.5M shares outstanding |
29M | 5.8M |
| Nov 03, 2022 |
10-Q filing | 25.5M shares outstanding |
26M | 5.8M |
| Aug 04, 2022 |
10-Q filing | 24.1M shares outstanding |
24M | 5.8M |
| May 05, 2022 |
10-Q filing | 24.0M shares outstanding |
24M | 5.8M |
| Mar 09, 2022 |
10-K filing | 23.3M shares outstanding |
23M | 5.8M |
| Nov 04, 2021 |
10-Q filing | 23.4M shares outstanding |
23M | 5.8M |
| Aug 05, 2021 |
10-Q filing | 23.3M shares outstanding |
23M | 5.8M |
| May 06, 2021 |
10-Q filing | 23.3M shares outstanding |
23M | 5.8M |
| Mar 25, 2021 |
10-K filing | 23.3M shares outstanding |
23M | 5.8M |
| Nov 10, 2020 |
S-1 filing: S-1 filing for common stock with Jefferies, SVB Leerink, and Piper Sandler as joint book-running managers and H.C. Wainwright & Co. as co-manager. |
20M | 5.8M |
| Nov 10, 2020 |
10-Q filing | 20.2M shares outstanding |
20M | 5.8M |
| Aug 13, 2020 |
10-Q filing | 20.2M shares outstanding |
20M | 5.8M |
| May 22, 2020 |
10-Q filing | 20.1M shares outstanding |
20M | 5.8M |
| Apr 07, 2020 |
S-1/A filing: Keros Therapeutics, Inc. is offering up to 5,750,000 shares of its common stock in an underwritten public offering. |
13M | 5.8M |
| Apr 01, 2020 |
S-1/A filing: Kerberos Capital Acquisition Corporation is offering 5,000,000 shares of common stock at an assumed initial public offering price of $15.00 per share. |
13M | 5M |
| Mar 16, 2020 |
S-1 filing: This is an S-1 filing related to an IPO of Common Stock. |
N/A | 0 |